Revvity, Inc. reported a total revenue of $664.8 million for the first quarter of fiscal year 2025, marking a 2% increase from $649.9 million in the same period last year. The growth was driven by a $11 million increase in the Diagnostics segment, which reached $324.4 million, and a $3.9 million rise in the Life Sciences segment, totaling $340.4 million. The company’s operating income from continuing operations also saw a significant increase, rising to $72.2 million from $44.1 million year-over-year. Net income for the quarter was $42.2 million, or $0.35 per diluted share, compared to $26 million, or $0.21 per diluted share, in the prior year.
The company experienced a decrease in total costs of revenue, which fell to $289.2 million from $294.9 million, contributing to an increase in gross margin from 54.6% to 56.5%. Selling, general, and administrative expenses decreased by 4% to $249.7 million, while research and development expenses rose by 6% to $53.6 million, reflecting ongoing investments in product development. The effective tax rate increased to 20.5% from 16.9%, primarily due to higher projected income in jurisdictions with elevated tax rates.
In terms of strategic developments, Revvity integrated its Applied Genomics business into a newly formed Life Sciences Solutions segment, which is now part of the Life Sciences segment. This restructuring aims to enhance operational efficiency and streamline product offerings. The company also continued its stock repurchase program, spending $153.6 million to buy back shares during the quarter, with $707.2 million remaining available for future repurchases.
Operationally, Revvity reported a cash balance of $1.14 billion as of March 30, 2025, with $1.5 billion in borrowing capacity under its senior unsecured revolving credit facility. The company’s cash flow from operating activities was $134.1 million, down from $150.1 million in the previous year, attributed to timing of collections and increased variable compensation. Looking ahead, Revvity anticipates continued revenue growth driven by demand in its Diagnostics and Life Sciences segments, while also managing the impacts of tariffs and market conditions on its operations.
About REVVITY, INC.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.